Hearing Loss, Sensorineural Clinical Trial
Official title:
A Phase 1b, Prospective, Randomized, Single-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety of FX-345 Administered as a Single Intratympanic Injection in Adults With Acquired Adult-Onset Sensorineural Hearing Loss
Verified date | April 2023 |
Source | Frequency Therapeutics |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This single-blind, placebo-controlled trial will be conducted to evaluate the safety of FX-345 administered as a single intratympanic injection in adults with acquired sensorineural hearing loss. The primary objectives are to assess the local safety, systemic safety, and pharmacokinetic (PK) profile to determine systemic exposure.
Status | Terminated |
Enrollment | 6 |
Est. completion date | April 12, 2023 |
Est. primary completion date | April 12, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 67 Years |
Eligibility | Inclusion Criteria: - Adult aged 18-67 years (inclusive) - Documented medical history consistent with acquired, adult onset, sensorineural hearing loss - At the Screening, Lead-in (Visit 2) and Treatment (Day 1) Visits, a pure tone average of 40- 80 dBHL at 500Hz, 1000Hz, 2000Hz, and 4000Hz in the potential study ear to be injected - Female participants must not be pregnant, breastfeeding, or lactating. Women of child-bearing potential must agree to use a highly effective contraceptive method and must have a negative urine pregnancy test. - Male participants must refrain from donating sperm and agree to be either abstinent or use a barrier method of contraception Exclusion Criteria: - Randomization in a FX-322 (laduviglusib and sodium valproate) clinical trial - Perforation of tympanic membrane or other tympanic membrane disorders that would interfere with the delivery and safety assessment of an intratympanic medication or reasonably be suspected to affect tympanic membrane healing after injection in study ear. This includes a current tympanostomy tube. - Any conductive hearing loss of greater than 15 dB at a single frequency or greater than 10 dB at two or more contiguous octave frequencies in the study ear at the Screening, Lead-in (Visit 2) or Treatment (Day 1) Visits, based on the investigator's judgment. - Active chronic middle ear disease or a history of major middle ear surgery, as an adult, in the ear to be injected. - Within 3 months of screening visit any of the following: 1) an intratympanic injection in either ear 2) treatment with steroids 3) onset of sudden sensorineural hearing loss - Evidence of or previous diagnosis of traumatic brain injury, Meniere's disease, or genetic hearing loss - History of head or neck radiation, significant systemic autoimmune disease, and/or chronic, recurrent clinically significant vestibular symptoms - Exposure to another investigational drug within 28 days prior to screening visit |
Country | Name | City | State |
---|---|---|---|
United States | Clinical Trial Site | San Antonio | Texas |
United States | Clinical Trial Site | San Antonio | Texas |
United States | Clinical Trial Site | Sarasota | Florida |
United States | Clinical Trial Site | Spartanburg | South Carolina |
Lead Sponsor | Collaborator |
---|---|
Frequency Therapeutics |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With Treatment-emergent Adverse Event(s) (TEAEs) | Baseline Through Day 90 | ||
Primary | Cmax | Maximum (peak) observed plasma drug concentration of FX04 and FX00 in cohort 1 participants | Data points taken pre-dose and 0.5, 1, 2, 4, 6, 24 hours post-dose | |
Primary | AUClast | Area under the concentration-time curve of FX04 and FX00 in cohort 1 participants | Data points taken pre-dose and 0.5, 1, 2, 4, 6, 24 hours post-dose | |
Primary | CL/F | Apparent total body clearance of FX04 and FX00 in cohort 1 participants | Data points taken pre-dose and 0.5, 1, 2, 4, 6, 24 hours post-dose | |
Primary | Vss | Apparent volume of distribution at steady state of FX04 and FX00 in cohort 1 participants | Data points taken pre-dose and 0.5, 1, 2, 4, 6, 24 hours post-dose | |
Primary | t1/2 | Elimination half-life of FX04 and FX00 in cohort 1 participants | Data points taken pre-dose and 0.5, 1, 2, 4, 6, 24 hours post-dose | |
Primary | Tmax | Time to reach maximum (peak) plasma drug concentration of FX04 and FX00 in cohort 1 participants | Data points taken pre-dose and 0.5, 1, 2, 4, 6, 24 hours post-dose | |
Primary | Elimination rate constant | The rate at which FX04 and FX00 is removed from the human system in cohort 1 participants | Data points taken pre-dose and 0.5, 1, 2, 4, 6, 24 hours post-dose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04281953 -
Impact on Quality of Life of Long-term Ototoxicity in Cancer Survivors
|
||
Not yet recruiting |
NCT05973669 -
MED-EL Remote Care Multi-Center Feasibility Study
|
N/A | |
Completed |
NCT04601909 -
FX-322 in Adults With Age-Related Sensorineural Hearing Loss
|
Phase 1 | |
Active, not recruiting |
NCT04479761 -
Sensory Integration of Auditory and Visual Cues in Diverse Contexts
|
N/A | |
Recruiting |
NCT05043207 -
A Study Protocol for the Validation of UAud in a Clinical Setting.
|
N/A | |
Recruiting |
NCT04070937 -
Correlation of Radiological Lesions With Vestibular Function in Patients With Bilateral Vestibulopathy
|
||
Recruiting |
NCT04066270 -
Inventory of Radiological and Vestibular Function in Cochlear Implant Candidates
|
||
Completed |
NCT03512951 -
Subjective Evaluation of a Sound Processing Method for Hearing Aids on Auditory Distance Perception
|
N/A | |
Completed |
NCT05855005 -
Direct-to-Consumer Hearing Aids and Listening Effort
|
N/A | |
Recruiting |
NCT05599165 -
Speech Perception in Bimodal Hearing
|
N/A | |
Completed |
NCT05101083 -
Speech Intelligibility in Quiet and Noise for New vs. Legacy Hearing Aids
|
N/A | |
Completed |
NCT05521308 -
Investigating Hearing Aid Frequency Response Curves
|
N/A | |
Completed |
NCT05072457 -
Benefit of Assistive Listening Device for Lateralization
|
N/A | |
Recruiting |
NCT05776459 -
Efficacy and Safety of AC102 Compared to Steroids in Adults With Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL)
|
Phase 2 | |
Completed |
NCT05086276 -
FX-322 in Adults With Acquired Sensorineural Hearing Loss
|
Phase 2 | |
Recruiting |
NCT06058767 -
Preschool Hearing Screening
|
N/A | |
Completed |
NCT05180630 -
Sound Quality Comparisons With Different Hearing Aid Couplings and Venting Systems
|
N/A | |
Completed |
NCT03613909 -
Acceptance of the CP950 Sound Processor
|
N/A | |
Active, not recruiting |
NCT03352154 -
Long Latency Auditory Evoked Potentials (P300) Outcomes in Patients With Unilateral Cochlear Implants
|
N/A | |
Completed |
NCT04629664 -
FX-322 in Adults With Severe Sensorineural Hearing Loss
|
Phase 1 |